Skip to main content

Table 2 Adverse reactions to subcutaneous immunotherapy in different cluster studies

From: Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: the SIMO study

Reference Study characteristics Build-up phase
No adverse reactions
First year of the maintenance phase
No adverse reactions
Local reaction Systemic reaction Local reaction Systemic reaction
n Age mean (95% confidence interval) Allergen No injections and visits Build-up duration (weeks) E D Total E D Total E D Total E D Total
Solá, 2018 110 31 (95% CI 28–34) Grass pollen and/or Olea europaea 2/2/2 2 3 50 53 2 6 8 0 7 7 0 1 1
Walker, 2001 [7] 22 32 (95% CI 22–64) Grass pollen 3/2/2/1/1/1/1 4 0 0 0 0 4 4 0 0 0 3
Crimi, 2004 [9] 15 32 (95% CI 21–54) Parietaria 2/2/2/2/1/1/1/1 7 0 0 0 0 0 0 3 0 0 0
Nanda, 2004 [10] 20 > 18 Cat hair and dander 2/2/2/2/1 5 0 0 0 1 0 1 0 0 0 0 0 0
Tabar, 2005 [11] 120 19 (SD9.8) Dermatophagoides pteronyssinus 4/3/2/2/2/2/1 6 6 0 6 1 3 4 1 4
Colás, 2006 [13] 41 34 (95% CI 18–51) Salsola kali 3/3/1 2 16 0 16 4 12 16 0 0 0 0 0 0
Subiza, 2008 [14] 22 30 (95% CI 12–60) D. glomerata, T. Paniceum 2/2/1 2 0 7 7 0 0 0 0 0 0 0 0 0
Zhang, 2009 [16] 45 25 (95% CI 15–36) Dermatophagoides pteronyssinus 3/2/2/2/2/2/1 6 11 0 11 5 0 5 7 6
Lou, 2012 [17] 25 12 (95% CI 9–13) Dermatophagoides pteronyssinus 3/2/2/2/2/2/1 6
Klimek, 2014 [18] 61 37 (SD 10.4) Grass and rye pollen 2/2/1 5 7 0 7 2 3 5
González-Gutiérrez, 2012 [6] 127 28 (SD 11.8) Grass pollen 2/2/2/1 4 8 24 32 3 11 14
177 30 (SD 12.3) Grass pollen 2/2/1 4 4 22 26 5 15 20
  1. n number of patients in active treatment group, E early reaction, appears less than 30 min from immunotherapy injection, D delayed reaction, appears 30 min or later from immunotherapy injection